Research programme: AZM 131 - Alizyme

Drug Profile

Research programme: AZM 131 - Alizyme

Alternative Names: AZM 131

Latest Information Update: 16 Jul 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alizyme
  • Developer Alizyme; Institute of Food Research
  • Class
  • Mechanism of Action Lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 16 Jul 1999 Discontinued-Clinical for Obesity in United Kingdom (Unknown route)
  • 24 Apr 1998 Investigation in Obesity in United Kingdom (Unknown route)
  • 23 Oct 1997 Yakurigaku Chou Kenkyusho has an option to license AZM 131 products in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top